Inhaled Furosemide Is Not Effective in Acute Asthma
| Autor: | Dana Hager, Deborah Shapiro, Felicia Dworkin, Sharon Feliciano, Laurie Posner, Denise Luks, Jill P. Karpel |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Pulmonary and Respiratory Medicine Time Factors Adolescent medicine.drug_class medicine.medical_treatment Critical Care and Intensive Care Medicine Furosemide Forced Expiratory Volume Bronchodilator Administration Inhalation medicine Humans Theophylline Lung volumes Metaproterenol Asthma Analysis of Variance Inhalation business.industry Nebulizers and Vaporizers Middle Aged medicine.disease Anesthesia Acute Disease Drug Therapy Combination Diuretic Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Chest. 106:1396-1400 |
| ISSN: | 0012-3692 |
| DOI: | 10.1378/chest.106.5.1396 |
| Popis: | As previous studies have suggested that inhaled furosemide may have a protective effect against certain types of provocative challenges in asthmatic subjects, we investigated the role of furosemide in treating acute asthma exacerbations. Twenty-four patients (n = 24) with acute asthma were entered into the study on presenting to the emergency department. They were blindly randomized to receive one of three drug regimens: (1) inhaled furosemide (40 mg) (n = 8); (2) inhaled metaproterenol (15 mg) (n = 7); or (3) the combination of furosemide (40 mg) and metaproterenol (15 mg) (n = 9). We measured FEV1 at entry (time 0) and 15, 30, 45, and 60 min after inhalation of the individual drugs or the combination from a face mask nebulizer. At entry, the three groups did not differ significantly in age (mean +/- SEM = 37.6 +/- 3.6, 38.5 +/- 3.6, and 41.0 years, respectively; p = 0.770), baseline FEV1 (1.01 +/- 0.27, 1.04 +/- 0.27, and 1.25 +/- 0.14 L, respectively; p = 0.620), or theophylline levels (2.87 +/- 1.8, 7.39 +/- 2.8, and 5.29 +/- 2.6 micrograms/ml, respectively; p = 0.498). Pretreatment and posttreatment potassium levels were similar among the three groups. Inhalation of furosemide alone resulted in a 14.9 +/- 10.5 percent change in FEV1 percent from baseline, which was not statistically significant. In contrast, metaproterenol alone resulted in a 42.9 +/- 15.2 percent increase in FEV1 percent (F ratio = 6.226; p = 0.0028). The combination of furosemide and metaproterenol resulted in a change in FEV1 percent that was not statistically different compared with metaproterenol alone (FEV1 percent = 41.9 +/- 12 percent). No significant adverse effects occurred in any of the groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|